Baijin Life Science Holdings Limited
MNNGF
$0.08
$0.000.00%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 127.60% | 127.58% | 183.15% | 183.01% | -22.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 127.60% | 127.58% | 183.15% | 183.01% | -22.40% |
| Cost of Revenue | 119.62% | 119.60% | 209.97% | 209.82% | -56.70% |
| Gross Profit | 141.36% | 141.36% | 121.46% | 121.33% | 312.92% |
| SG&A Expenses | -6.12% | -6.14% | 79.00% | 78.91% | 40.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -398.40% | -398.29% | -499.22% | -499.22% | 185.47% |
| Total Operating Expenses | 23.44% | 23.43% | 151.74% | 151.62% | -24.64% |
| Operating Income | 290.51% | 290.48% | 119.82% | 119.81% | 30.67% |
| Income Before Tax | 66.48% | 66.48% | 130.59% | 130.58% | -293.56% |
| Income Tax Expenses | -25,070.00% | -25,090.00% | -- | -- | -- |
| Earnings from Continuing Operations | 129.29% | 129.29% | 17.69% | 17.73% | -294.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 275.61% | 275.36% | -- | -- | -- |
| Net Income | 215.82% | 215.81% | -169.55% | -169.49% | -225.07% |
| EBIT | 290.51% | 290.48% | 119.82% | 119.81% | 30.67% |
| EBITDA | 324.84% | 324.80% | 181.70% | 181.66% | 34.46% |
| EPS Basic | 200.00% | 200.00% | -200.00% | -200.00% | -150.00% |
| Normalized Basic EPS | 450.00% | 450.00% | -300.00% | -300.00% | -300.00% |
| EPS Diluted | 200.00% | 200.00% | -200.00% | -200.00% | -150.00% |
| Normalized Diluted EPS | 450.00% | 450.00% | -300.00% | -300.00% | -300.00% |
| Average Basic Shares Outstanding | 8.89% | 8.89% | 6.25% | 6.25% | 1.53% |
| Average Diluted Shares Outstanding | 8.89% | 8.89% | 6.25% | 6.25% | 1.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |